Blood tests (also called liquid biopsies), designed to identify the presence of multiple cancers before symptoms occur, are beginning to become reality in the UK. They offer the opportunity to screen for and diagnose cancer earlier, potentially increasing the range of treatment options and improving long-term survival rates.

In this session experts in the prevention and early diagnosis of cancer will discuss the potential of multi-cancer early detection (MCED) tests. Researchers will share their views and lessons from studies such as SYMPLIFY, in which an MCED test is being used to detect more than 50 types of cancer in patients with non-specific symptoms. They will also discuss the views of cancer patients and public attitudes to this type of testing before taking part in a panel discussion and Q&A.

By the end of the session, attendees will have a better understanding of the potential of MCED tests to reduce the burden of cancer. Attendees will have learnt lessons from existing trials as well as understood the views of patients and the public.

Chair

• Professor Emma Crosbie – University of Manchester and Deputy Chair of NCRI Screening, Prevention & Early Diagnosis Group, UK

Speakers

• Ms Sue Duncombe – NCRI Consumer Forum and PPI contributor, UK
• Dr Catherine Elliott – Cancer Research UK, UK
• Dr Laura Marlow – King’s College London, UK
• Professor Mark Middleton – University of Oxford, UK
• Professor Peter Sasieni – King’s College London and Chair of NCRI Screening, Prevention & Early Diagnosis Group, UK
• Speaker TBC

For more details and to register click here.